BioMarin submits FDA sNDA for VOXZOGO in hypochondroplasia
Bitget2026/10/09 13:05BioMarin filed an sNDA with the FDA seeking to expand VOXZOGO to treat hypochondroplasia. Regulatory submissions to the EMA, other health authorities remain on track. If cleared, VOXZOGO would become the first targeted hypochondroplasia therapy, positioning a potential 2027 launch. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610090905PR_NEWS_USPR_____SF66672) on October 09, 2026, and is solely responsible for the information contained therein.
- BioMarin filed an sNDA with the FDA seeking to expand VOXZOGO to treat hypochondroplasia.
- Regulatory submissions to the EMA, other health authorities remain on track.
- If cleared, VOXZOGO would become the first targeted hypochondroplasia therapy, positioning a potential 2027 launch.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Trader Gu Jingci: November 9 Bitcoin/Ethereum Trading Strategy and Market Analysis
United States Dollar Index remains subdued as lower oil prices ease inflation pressure
Crypto prices
More
